The cytokines profile peculiarities in patients with bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 272s Year: 2001
Infectional factors influences on expressiveness of inflammatory process and structural changes in bronchial mucosa at COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 576s Year: 2006
Peculiarities of clinical-functional manifestations in severe bronchial asthma patients depending on the characteristics if local immunity Source: Annual Congress 2009 - Asthma and comorbid conditions Year: 2009
Functional, clinical evolution and cellular inflammatory pattern in induced sputum in patients with difficult-to-control asthma Source: Annual Congress 2011 - Update on monitoring airway diseases Year: 2011
The level of anti-inflammatory cytokine IL-10 in patients with chronic obstructive pulmonary disease of varying severity Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013
An evaluation of circulating cytokines milieu in patients with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 311s Year: 2002
Evolution of cellular inflammatory pattern in induced sputum in patients with mild-moderate asthma for five years Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers Year: 2011
Clinical markers of disease severity in the assessment of airway inflammation in patients with persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 335s Year: 2001
The effects of morphological remodeling of the bronchi on the neocollagenesis processes in patients with COPD stage 2 during exacerbation Source: Annual Congress 2011 - COPD: human studies Year: 2011
Redox status, metals-microelements and cytokines in blood of bronchial asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 680s Year: 2006
Dynamic of proinflammatory cytokines system and nonspecific markers of inflammation in patients with COPD before and after treatment with broncholitics Source: Eur Respir J 2006; 28: Suppl. 50, 38s Year: 2006
Cytokine regulation of the chronicle inflammation of bronchial asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 590s Year: 2005
The relationship between bronchial inflammation and markers of disease progression in COPD Source: Eur Respir J 2003; 22: Suppl. 45, 179s Year: 2003
Inhibiting effect of influenza vaccinations on serum eotaxin level in patients with allergic bronchial asthma and chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 134s Year: 2004
Evidence of mast-cell activation in a subset of patients with eosinophilic chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: 325-331 Year: 2002
Treatment: how does inflammatory phenotype influence response to treatment in airway disease? Source: Annual Congress 2007 - Inflammatory phenotypes in airway disease Year: 2007
The impact of vaccination on the dynamics of bronchial and systemic inflammation in patients with COPD and CHD Source: International Congress 2017 – COPD management Year: 2017
Assessment of innate immunity mediators in the lung of COPD patients: relation with disease manifestations Source: Virtual Congress 2020 – Host-microbe interactions and their influence on lung disease onset and severity Year: 2020
Opioid-neurotensin hybrid influences pulmonary inflammatory process in murine model of non-atopic asthma. Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
Periostin as a marker of Th2-related inflammation in patients with different types of chronic obstructive airway disease Source: International Congress 2017 – Biomarker-based asthma control Year: 2017